29/08/2026
Open-Angle Glaucoma: Sustained-Release Micro-Implant Offers Long-Duration IOP Control
Glaucoma treatment is increasingly moving beyond daily eye drops. One of the newer approaches is an intracameral sustained-release implant that delivers a prostaglandin directly inside the eye over an extended period.
The technology highlighted in the news card is iDose® TR (travoprost intracameral implant), a titanium-based drug-delivery system designed for patients with open-angle glaucoma or ocular hypertension. It is FDA-approved to reduce elevated intraocular pressure (IOP).
1. What Is iDose TR?
iDose TR is a small travoprost-releasing intracameral implant.
Instead of requiring the patient to instill topical prostaglandin drops every day, the implant is placed inside the anterior chamber and continuously releases a preservative-free formulation of travoprost.
The implant contains 75 µg of travoprost and uses a membrane-controlled drug-release system.
2. Where Is the Implant Placed?
The implant is delivered through a small clear-corneal incision under appropriate surgical conditions.
It is positioned at the iridocorneal angle, with an anchor securing the implant through the trabecular meshwork into the scleral tissue.
This location allows travoprost to be released directly into the anterior chamber.
3. How Does It Work?
Travoprost is a prostaglandin analog that lowers IOP primarily by increasing uveoscleral outflow.
The iDose TR system provides prolonged local delivery rather than relying on repeated topical administration.
Conceptually:
Implant → controlled travoprost release → increased aqueous outflow → reduced IOP
This approach is particularly relevant because adherence to long-term glaucoma eye-drop therapy can be challenging.
4. What Does the Clinical Evidence Show?
Clinical trials evaluated travoprost intracameral implants in patients with open-angle glaucoma or ocular hypertension.
A Phase 3 randomized study included 590 participants and compared two travoprost implant models with twice-daily timolol.
Earlier Phase 2 data followed patients for 36 months. At three years, 63% of patients receiving the fast-eluting implant and 69% receiving the slow-eluting implant had well-controlled IOP while using the same number of or fewer topical IOP-lowering medications than at screening.
These findings support the potential for long-duration IOP control and reduced dependence on topical medication, although individual outcomes vary.
5. Why Is the “Up to 3 Years” Claim Important?
“Up to 3 years” does not mean every patient will experience identical IOP control for exactly three years.
Duration of therapeutic effect can vary, and clinical management still requires monitoring.
6. What Did the FDA Approve?
The U.S. FDA approved iDose TR in December 2023 for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
Importantly, this is an FDA-approved treatment—not merely an investigational device.
In January 2026, the FDA also approved a labeling supplement permitting re-administration under specified conditions, representing an important update to the treatment protocol.
7. Why Could This Matter for Patients?
Traditional glaucoma therapy often depends on consistent daily eye-drop use.
Problems can include:
Forgetting doses
Difficulty correctly instilling drops
Multiple medications and dosing schedules
Ocular-surface exposure to topical medications
Long-term adherence challenges
A sustained-release approach attempts to shift some of this burden from daily self-administration to a longer-duration procedural treatment.
8. Does It Replace Glaucoma Monitoring?
No.
Even with a sustained-release implant, glaucoma remains a chronic disease requiring ongoing monitoring.
Clinicians still need to evaluate:
IOP
Optic nerve status
Retinal nerve fiber layer
Visual fields
Corneal health
Medication/treatment response
Potential adverse effects
The goal is not simply to lower one IOP measurement, but to reduce the patient's long-term risk of glaucomatous damage.
🔬 Key Clinical Concept
iDose TR is not a mechanical trabecular bypass stent.
It is a travoprost-eluting intracameral implant designed to provide sustained drug delivery.
Its titanium reservoir and membrane-controlled release system allow medication to be delivered continuously inside the eye after implantation.
👁️ For Eye-Care Professionals
The significance of sustained-release glaucoma therapy extends beyond drug delivery.
It represents a broader shift toward procedural pharmacotherapy, where treatment is administered through an intervention and designed to reduce reliance on daily topical medications.
For optometrists and ophthalmologists, the important considerations remain patient selection, angle anatomy, corneal endothelial health, IOP response, adherence history, and appropriate long-term follow-up.
Bottom Line
iDose TR represents a different way of delivering glaucoma medication: instead of relying exclusively on daily eye drops, a small intracameral implant continuously releases travoprost inside the eye.
Clinical studies have demonstrated IOP-lowering effects extending to 36 months, while FDA approval covers the treatment of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
The technology does not eliminate the need for glaucoma monitoring—but it offers an important option for reducing the burden of chronic topical therapy.
Our youtube channel at: https://youtube.com/?si=RzqNscamdIgCG23a
Sources
U.S. FDA — iDose TR Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218010s004lbl.pdf
ClinicalTrials.gov — iDose TR Phase 3 Trial (NCT03519386)
https://clinicaltrials.gov/study/NCT03519386
PubMed Central — Travoprost Intracameral Implant: 12-Month Results
https://pmc.ncbi.nlm.nih.gov/articles/PMC10912401/
PubMed Central — Prostaglandin Intracameral Implants for Ocular Hypertension and Open-Angle Glaucoma
https://pmc.ncbi.nlm.nih.gov/articles/PMC11791955/
iDose TR — Official Prescribing Information
https://www.idosetr.com/prescribing-information/
iDose TR — Official Website
https://www.idosetr.com/
DailyMed — iDose TR (Travoprost Intracameral Implant)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f6d3e2-8328-47df-972c-23008f4a1c1c
FDA — iDose TR Approval Review
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218010Orig1s000SumR.pdf
Ophthalmology and Therapy — Travoprost Intracameral Implant Clinical Trial
https://link.springer.com/article/10.1007/s40123-024-00898-y
Daily eye testing. 80k on FB. Spreading eye knowledge and awareness